Treating inflammatory bowel diseases in the 21st century: individualized therapy and telemedicine
Authors:
Milan Lukáš
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE, a. s., a 1. LF UK v Praze
Published in:
Vnitř Lék 2021; 67(4): 201-205
Category:
Main Topic
Overview
Monitoring and therapy in patients with inflammatory bowel disease have been completely changed with regards of monitoring tolls, therapeutic aims and pursuance of therapeutic responses since of beginning this century. Uncomparable higher access to the modern and innovative conservative treatment requires precise consideration how to choice optimal drug at the therapy beginning. Crohn´s disease and ulcerative colitis prevalence is stable increasing and within next ten years has been expanded more than 20–30%. Higher IBD prevalence will dictate implementation of new tools for long-term follow up. Telemedicine seems to be the most important project implemented in those patients with chronic and uncurable disorders.
Keywords:
Crohn´s disease – Ulcerative colitis – Telemedicine
Sources
1. Lukáš M. Cílená a biologická léčba v gastroenterologii. In Cílená a biologická léčba Edited by: Vladimír Tesař, Mladá fronta 2019.
2. Charpentier C, Salleron J, Savoye G et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2014; 63: 423–432 doi: 10.1136/ gutjnl-2012-303864.
3. Pariente B, Cosnes J, Danese S et al. Development of the Crohn´s disease digestive damage score, the Léman score. Inflamm Bowel Dis 2011; 17: 1415–1422.
4. Peyrin-Biroulet L, Sandborn WJ, Sands BE et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat to target. Am J Gastroenterol 2015; doi: 10.1038/ajg.2015.233.
5. Pariente B, Mary JY, Danese S et al. Development of the Léhmann index to assess digestive tract damage in patients with Crohn´s disease. Gastroenterology 2015; 148(1): 52–63.
6. Ďuricova D, Pfeiferová M, Bortlík M et al. Kvalita života pacientů s idiopatickými střevními záněty v České republice – multicentrická studie. Gastroent Hepatol 2018; 72(1): 11–19.
7. Jowett SL, Seal CJ, Barton JR et al. The short inflammatory bowel disease quostionaire is reliable and responsive in clinically important change in ulcerative colitis. Am J Gastroenterol 2001; 96(10): 2921–2928.
8. Colombel JF, Panaccione R, Bossuyt P et al. Effect of tight control management of Crohn´s disease (CALM): a multicenter, randomized controlled phase 3 trial. Lancet 2017; doi.org/10.1016/ S0140-6736(17)32641-7.
9. Yzet C, Ungaro B,Bossuyt P et al. Endoscopic and deep remission at 1 year prevents disease progression in early Crohn´s disease: long term data from CALM. J Crohn´s Colitis 2019; 13: S25–S26.
10. Khanna R, Bressler B, Levesque BG et al. Early combined immunosupression for the management of Crohn´s disease (REACT): a cluster randomized controlled trial. The Lancet 2015; doi.org/10.1016/S0140-6736(15)00068-9.
11. Bortlík M, Ďuricová D, Kohout P et al. Doporučení pro podávání biologické léčby. Čtvrté přepracované vydání. Gastroenterol Hepatol 2019; 73(1): 15–27.
12. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23): 2462–2476.
13. Ďuricová D, Lukáš M. Který typ biologické léčby zvolit u nemocných s IBD? Remedia 2019; 29: 67–71.
14. Lukáš M. Biologická léčba idiopatických střevních zánětů. In: Pavelka K, Arenberger P, Lukáš M et al (eds). Biologická léčba zánětlivých autoimunitních onemocnění v revmatologii, dermatologii a gastroenterologii. Praha: Grada 2014.
15. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010; 362(15): 1383–1395.
16. Duricova D, Dvorakova E, Hradsky O et al. Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation. Inflamm Bowel Dis. 2019; 25(4): 789–796.
17. Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S et al. Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. J Crohns Colitis. 2019; 13(Suppl 1): S041–S042.
18. Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Dermatol Ther. 2017; 30(3).
19. Lukáš M. Klinický význam monitorování farmakokinetiky biologických léčiv u nemocných s idiopatickými střevními záněty. In: Novinky v gastroenterologii. Edited by Julius Špičák, Grada 2017.
20. Schreiber S, Ben Horin S, Ye BD et al. Development of novel autoinjector of subcutaneous infliximab CT-P13: Phase 1 Randomized open – label, single dose trial to compare to pharmacokinetics and safety to prefilled syringe in healthy subjects. J Crohn´s Colitis 2019; 13: S458.
21. Pudilová K, Kolář M, Duricová D et al. Early vedolizumab trough level are not associated with a short term response in patients with inflammatory bowel disease. J Crohn´s Colitis 2019; 13: S356.
22. Papamichael K, Cheifetz A S. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug.Curr Opin Gastroenterol 2019; 35: 302–310.
23. Ministerstvo zdravotnictví ČR . Posouzení realizovatelnosti vybraných oblastí Národní strategie elektronického zdravotnictví. Verze 2.04. Praha, 2016. Licencováno pod CC BY 4.0, licenční podmínky dostupné z: http://creativecommons.org/licenses/by/4.0/.
24. Doporučení výboru ČSKB 2006. Správné zavádění a používání POCT. Dostupné z: www.cskb.cz
25. Elkjaer M. E-health: web guided therapy and disease-self management in ulcerative colitis. Impact on disease outcome, quality of life and complience. Dan Med J 2012; 59(7): B4478.
26. de Jong M et al. Development and Feasibility Study of a Telemedicine Tool for All Patients with IBD: MyIBDcoach. Inflamm Bowel Dis. 2017; 23(4): 485–493.
27. de Jong MJ et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017(2); 390(10098): 959–968.
28. Singh S, Brill JV, Proudfoot JA, Metcalfe L, Vu L, Sandborn WJ, Kosinski LR. Project Sonar: A Community Practice-based Intensive Medical Home for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018; 16(12): 1847–1850.
29. Atreja A, Khan S, Rogers JD, Otobo E, Patel NP, Ullman T, Colombel JF, Moore S, Sands BE. HealthPROMISE Consortium Group. Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. JMIR Res Protoc. 2015; 4(1): e23.
30. Malíčková K, Pešinová V, Kolář M, Lukáš M. POCT systém detekce hladin fekálního kalprotektinu při telemonitoringu pacientů s idiopatickými střevními záněty. Klin Biochem Metabol 2019; 27(48): 72–77.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2021 Issue 4
Most read in this issue
- Chronic obstructive pulmonary disease: diagnosis and treatment of stable phase of disease; personalized treatment approach using phenotype features of the disease Summary of the 2020–2021 Czech Pneumological and Phthiseological Society position paper
- Thymoma – disease of many faces
- Targeted and biological drugs in the treatment of inflammatory rheumatic diseases
- Biologic therapy for dyslipidemia